ABSTRACT. Numerous reports have shown that intravascular lipid infusion may cause pulmonary dysfunction in a variety of species, including humans. To determine the effects of parenteral lipid on neonatal pulmonary hemodynamics, lung fluid filtration, and respiratory gas exchange, we measured pulmonary arterial and left atrial pressures, cardiac output, lung lymph flow, lymph and plasma protein concentrations, and partial pressures of oxygen and carbon dioxide in arterial blood of 11 awake chronically catheterized lambs that received a 2-3 h control infusion of glucosesaline solution followed by Intralipid at a dose of 67.5, 125, or 250 (mg/h)/kg body weight for 6 h. Intralipid caused an acute dose-dependent increase in pulmonary arterial pressure, with no significant change in cardiac output or left atrial pressure. The pulmonary hypertension, which lasted for at least 2 h, was accompanied by a >50% increase in lung lymph flow and a significant decrease in lymph protein concentration relative to plasma protein concentration. Pulmonary artery pressure gradually decreased to control values during the final 2 h of lipid infusion, but lymph flow remained 35% above control and lymph protein concentration remained low. Lipid infusion also was associated with a modest decrease in Pa02. Both arterial and venous administration of lipid gave similar results. In separate studies, lipid infusion caused a significant increase in plasma concentrations of thromboxane B,, the stable metabolite of thromboxane A2, without affecting plasma concentrations of 6-keto prostaglandin F,,, the stable metabolite of prostacyclin. Pretreatment with imidazole, which attenuated the lipid-induced increase in thromboxane B2 concentration, completely blocked the pulmonary hemodynamic response to lipid. Moreover, in the presence of imidazole there was no significant change in any of the other measured variables during lipid infusion. These results suggest that 1) lipid infusion causes a sustained increase in pulmonary microvascular pressure, most likely from constriction of lung vessels distal to sites of fluid exchange; and 2) thromboxane Az is at least partly responsible for these changes. (Pediatr Res 22:714-719, 1987) Abbreviations 'l'x, thromboxane 6-keto-PGF,,, 6-keto prostaglandin F,,
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The mechanisms by which lipid infusion may interfere with respiratory gas exchange and cause pulmonary vasoconstriction in humans remains unclear. One possible explanation is that emulsified fat lodges in lung capillaries and thereby blocks blood flow. In support of this theory, several groups of investigators (6-8) have noted the presence of fat in the pulmonary microcirculation of infants who have died after treatment with intravenous lipid. However, similar fat deposits occur in the lung vasculature of infants who have not received parenteral lipid (9). This observation raises doubt about the possible link between lipid infusion and pulmonary emboli.
An alternative explanation for the lung dysfunction that develops during lipid infusion is that release of vasoactive substances may disrupt the normal relationship between pulmonary perfusion and ventilation. At least two previous reports have provided evidence in support of such a theory. McKeen ct a/. (10) found that pretreatment of sheep with indomethacin, a prostaglandin synthesis inhibitor, prevented the increase in pulmonary arterial pressure and lung lymph flow associated with intravenous infusion of emulsified fat. In a subsequent study performed with isolated adult rabbit lungs, Gurtner ct a/. (1 1) showed that addition of lipid emulsion to the perfusate caused vasoconstriction and significant increases in the concentrations of two cyclooxygenase-derived products of arachidonic acid metabolism, TxB2 and 6-keto-PGF,,, in pulmonary venous outflow liquid.
The purpose of this work was to study the effects of lipid infusion on pulmonary vascular pressures and lung fluid filtration in unanesthetized newborn lambs. We found that lipid, delivered either through a systemic vein or artery, caused increases in pulmonary artery pressure and lung lymph flow which were associated with increases in plasma concentrations of TxB2. Pretreatment of the lambs with imidazole, an inhibitor of thromboxane synthesis, prevented both the chemical and physiological changes, suggesting that specific products of arachidonic acid metabolism. rather than embolic phenomena, probably account for the pulmonary abnormalities that develop during intravenous lipid therapy.
MI: 1'1 IOIIS I'rc~/~orc~iio~~ /i)r c.\-/)cJr.ri~lc,tii\. Wc \urgicall! prepared I I n oborn lambs for mcasurcmcnt 01' systemic and p~rlmonar! \:IScular pr-css~rrcs. car-diirc oi~tl,ut. and lung Iynipli flo\v. uliicli under-stcady statc conditrons reflects net transvascular filtration of fluid in tlic lungs ( 12, 13) . 134 mctliods prc\ iousl! dcscrihcd (14. 1 S), cacti lamb had two thor-acotoriiics under halothane :~nd ~iitrous oxide anesthesia dclivcrcd through a piston-t!.l?c rcspirator-. 13cfo1-c and alter-s~rrgcr) the lambs remained with their ewes li)r li.cding and \var.mtli.
Iluring the first thoracotomy. pcr1i)rmcd when the Iambs Lvcre lcss than 3 days old. we inscr-tcd polyvinyl catlictcrs directl! into thc pulmonary arter-y and lcfl atriurii. and wc also ~~l a c c d a 3 I-r tlicrmistor ((iould Statham. model S1'5003. (;auld. Inc.) in the pulmonary artcs\'. During the sarnc proced~~sc. \vc threadcd cathctcr-s into the abdornin:~l aorta and inkrior \.cnn c a \ a tliro~rgli ;I leg incision. Alicr I-cco\cr) from the first surgcr!. 6-keto-PGF,,, we carried a 2-ml sample of lamb plasma, preincubated with activated charcoal to remove TxBz and 6-keto-PGF,,,, through the purification process used for the 1-ml experimental plasma samples. Appropriate TxBz or 6-keto-PGF,,, standards were added to each of these evaporated residues. This procedure yielded reproducible standard curves with linear titration from 1-100 pg TxBz and 10-500 pg 6-keto-PGF,,. Antiscra to TxB2 or 6-keto-PGF,,, were obtained from Seragen Inc. Concentrations are expressed as free acid. Fig. 1 ). Lung lymph flow increased and the concentration of protein in lymph relative to that in plasma decreased as pulmonary hypertension developed during the acute phase of these studies. In the steady state period, 4-6 h after the start of the lipid infusion, pulmonary arterial pressure decreased to a value at or just above control; lymph flow also decreased but remained 35% greater than it was during the control period. The concentration of protein in lymph relative to that in plasma remained less than the control value during the steady state period. Lipid infusion had a dose-dependent effect on both pulmonary arterial pressure and lung lymph flow during the acute, but not during the steady state, phase of these experiments (Fig. 1, Table  1 ). At the lowest dose, 67.5 (mg/h)/kg, lipid had no significant effect on any of these measurements. At the highest dose. 250 pressure elevation studies because lung microvascular pressure increased by more than 10 torr, considerably greater that the pressure rise that occurred during lipid infusion. The point that we wish to emphasize is that the slopes of the two lines are virtually identical. indicating that protein sieving was similar in the two sets of experiments and that the probable source of the increased lymph flow during lipid infusion was increased filtration pressure.
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The fact that lymph flow remained high and lymph protein concentration remained low during the steady state phase of the lipid infusion studies, when pulmonary arterial pressure was almost back to control values, suggests that lipid caused a persistent increase in lung vascular resistance distal to sites of fluid exchange, possibly in pulmonary venules. Thus, the pulmonary hemodynamic effects of lipid infusion include an initial dosedependent increase in pulmonary vascular resistance, associated with elevated plasma concentrations of thromboxane, followed by a persistent increase in fluid filtration pressure. It is likely that this pressure rise occurs in the venular and microvascular segments of the pulmonary circulation, with a secondary increase in fluid filtration into the lungs. All of these changes can be blocked by concurrent administration of imidazole, which attenuates the lipid-induced increase in the concentration of thromboxane in plasma.
We have no reason to believe that the lipid-induced increase in lymph flow was the result of altered lung vascular permeability to protein. The concentration of protein in lymph decreased during lipid infusion, whereas lymph protein concentration usually increases or remains constant when endothelial injury occurs (13, 22) . It is also unlikely that the increase in lymph flow was the result of pulmonary fat embolism, as intraarterial infusion of lipid had the same effect as did intravenous infusion. Furthermore, McKeen rt ul. (10) previously showed that heparin administration to adult sheep at a dose suficient to clear their plasma or triglycerides did not alter their pulmonary vascular and lymph flow response to lipid infusion.
The source of thromboxane during lipid infusion is unknown. It is possible that the lipid infusate itself contains free arachidonic acid, which has been shown to constrict pulmonary venules in isolated, perfused dog lungs (23). Exogenous arachidonic acid infused into newborn lambs causes all of the hemodynamic changes that we observed during lipid infusion, and it also increases plasma concentrations of TxB2 without increasing 6-keto-PGF,,, (24). In addition, lipid infusion may stimulate endogenous tissue release of TxA2, with secondary pulmonary vasoconstriction.
In addition to their potent effect on pulmonary vascular smooth muscle, arachidonic acid metabolites of both the cyclooxygenase and lipoxygenase pathways may cause bronchoconstriction (25) with resultant mismatch of ventilation and perfusion. Inhibition of Tx synthetase either attenuates or prevents these changes from occurring in sheep with either complement-mediated or endotoxin-induced lung injury (26, 27 ). We did not measure lung mechanics in our lambs, but it is possible that a change in airway rcsistancc may havc contributed to the dccrcasc in arterial oxygenation associatcd with lipid infusion. Our-r.csc~lts are consistent with the previous observation that cyclooxygcnasc inhibition lcsscncd thc cff'cct of lipid infusion o n arterial ox!genation in rabbits with lung injury from olcic acid (18). it is cxtremcly unlikely that the modest increase in lung fluid filtr-ation that occurred during only 6 h ol' lipid administration had any influence on respiratory gas exchange in our lambs.
Certain fcaturcs of this work nay have important clinical implications conccr-ning lipid delivery in patients with lung discase. First, thcrc appears to be a threshold dose below which lipid docs not causc an apprcciablc incrcasc in lung fluid filtration. Our data suggest that in healthy lambs. an infusion rate of 67.5 (mg/h)/kg body weight. or I .6 (g/day)/kg. does not signilicantly increase cithcr pulnionary arterial pressure or lung Ihmph flow. Second. because the acutc pulrnonarq vascular rcsponsc to lipid is considerably greater than the steady state response. it seems sensible that lipid should be given continuously. rather than intermittently, over ;I 24-11 period in order to avoid the abrupt changes associatcd with initiation of infusions. Finally. it is possible that these potentially advcrsc cfkcts of lipid infi~sion can be prcvcnted by dcvelopmcnt of safe and ctfcctivc methods to inhibit thromboxanc synthesis cithcr by pharmacological means or by altering the fatty acid composition of the infusatc. If lipid infusion alrects pulmonar> vascular resistance. lung fluid liltration. and ar-tcrial oxygenation in human infr~nts as it docs in lambs. then suitable measures to inhibit these effects may help to prevent the development of pulmonary edema and respirator> dysfunction in babies that req~lirc parcntcral nutrition with fat.
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